US FDA Staff Weigh Urinary Effect of Valeant Pharmaceuticals International, GlaxoSmithKline Drug, Advisory Panel to Review Potiga on Wednesday

August 9, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- U.S. drug reviewers are concerned about urinary retention seen in some patients treated with an experimental epilepsy medicine from GlaxoSmithKline (GSK.L) and Valeant Pharmaceuticals (VRX.N), according to documents released on Monday.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

GlaxoSmithKline Food and Drug Administration (FDA) Valeant Pharmaceuticals International